Research Summary

Analyzed using Evidence Intelligence™

Liraglutide may reduce stroke recurrence in type 2 diabetes patients

Key finding

Hazard ratio, 0.56 (95% CI, 0.34-0.91); P = .02

This study investigated the effects of liraglutide on stroke recurrence in patients with type 2 diabetes, finding a lower rate of recurrence compared to the control group.

Evidence strength

Moderate confidence

Study type

RCTs

Follow-up

Medium-Term (3–12 mo)

Some Concerns bias

Last updated July 6, 2026

Quick read

Study at a glance

The essential study design details in one scan.

Population

Young Adult (19–39), Middle Aged (40-64), Male, Female, Asia-Pacific (APAC), with T2 Diabetes

Intervention

Liraglutide

Study type

RCTs

Follow-up

Medium-Term (3–12 mo)

Primary outcome

Stroke recurrence

Comparator

Standard treatment

Plain-language summary

What this paper says

A plain-language read of the study's main message and where it applies.

Study focus

This study investigated the effects of liraglutide on stroke recurrence in patients with type 2 diabetes, finding a lower rate of recurrence compared to the control group.

Clinical relevance

The findings suggest that liraglutide not only aids in diabetes management but may also play a crucial role in reducing the risk of stroke recurrence. This is significant for clinicians as it highlights the potential of liraglutide to improve patient outcomes in a population at high risk for vascular events.

Keep in mind

The study's sample size may limit the generalizability of the findings. The follow-up period of 90 days may not capture long-term outcomes. Potential confounding factors were not fully controlled for in the analysis.

Published in

Journal Reference

Publication details and source links for this paper.

Huili Z, Bin Y, Longyan L, et al. Liraglutide and Stroke Recurrence in Patients with Type 2 Diabetes. JAMA Internal Medicine. 2025;186(1):46-54. doi:10.1001/jamainternmed.2025.5684

View DOI View on PubMed View on PMC

Save this study and add notes to your research library.

Main Effects

Liraglutide reduced stroke recurrence to 7.9% compared to 13.8% in the control group (p=0.02).

The incidence of ischemic stroke was lower in the liraglutide group at 7.6% versus 13.5% in controls (p=0.02).

A higher proportion of patients achieved a modified Rankin Scale score of ≤ 1 in the liraglutide group (87.3%) compared to controls (77.8%).

Evidence network

How this study fits

Understand where this research contributes within the broader evidence network.

Evidence Context

This study contributes evidence to Liraglutide and Acute pancreatitis, All-cause mortality, Gastrointestinal disorders incidence, and 8 more.

This study contributes evidence to

Intervention

Liraglutide

Outcome

Acute pancreatitis

Evidence topic

Cardiovascular Risk

Primary intervention

Liraglutide

Primary outcomes

Acute pancreatitis
All-cause mortality
Gastrointestinal disorders incidence

Evidence topics

Cardiovascular Risk GLP-1 Receptor Agonists Liraglutide

Primary intervention

Liraglutide

Primary outcomes

Acute pancreatitis All-cause mortality Gastrointestinal disorders incidence

Evidence relationships

Intervention and outcome relationships this study adds to the evidence network.

Evidence pairs

Relationships

Evidence topics

contributes_evidence

Editorial context

Why this study matters

See why this paper is useful beyond its individual results.

Evidence network role

This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.

Moderate contributionModerate confidenceNetwork score: 72

Why it is useful

Contributes to 11 evidence relationships
Includes primary outcome data
Linked to 3 direct semantic evidence topics

Topic contributions

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Evidence topic

Liraglutide → Symptomatic intracranial hemorrhage

Evidence profile

NoneNo ChangeClinical Outcomes

Unlock full evidence details

Unlock full evidence analysis

Create a free account to access effectiveness ratings, evidence strength and depth scores, consistency analysis, and direct links to all supporting studies.

Evidence Suggest

Stroke recurrence was reduced by 0.56 events with liraglutide (p=0.02).
Ischemic stroke incidence decreased by 0.55 events in the liraglutide group (p=0.02).
Patients on liraglutide had 1.95 times higher odds of achieving better recovery outcomes.

Who this applies to

Adults aged 40-75 with type 2 diabetes.
Patients with a history of stroke or transient ischemic attack.

Keep in Mind

Results may not apply to younger populations or those without diabetes.
The study did not include patients with acute pancreatitis.
Findings are based on a short follow-up period, necessitating further research.

Between the Lines

The study's sample size may limit the generalizability of the findings.
The follow-up period of 90 days may not capture long-term outcomes.
Potential confounding factors were not fully controlled for in the analysis.

Unlock Full Analysis

Create a free account to unlock the bias score, detailed effectiveness analysis, and clinical outcomes for this study.

Already have an account?

Connected Evidence

Explore related studies, evidence collections, and research questions.

Relationships organized using the Dediabetes Evidence Intelligence™ framework.

This study contributes to evidence on GLP-1 Receptor Agonists and Ischemic stroke, GLP-1 Receptor Agonists and Modified Rankin Scale score ≤ 1.

Related evidence relationships

Explore in Evidence Archive

This study contributes to the evidence on the following intervention-outcome relationships.

GLP-1 Receptor AgonistsIschemic stroke

Medications

1 studies

Detailed evidence

GLP-1 Receptor AgonistsModified Rankin Scale score ≤ 1

Medications

Latest published studies

recency_collection

Published within the last 2 years.

Generated from the study's connected evidence using Evidence Intelligence™.

Does GLP-1 Receptor Agonists improve cardiovascular outcomes?

Emerging Evidence

GLP-1 Receptor Agonists may improve Cardiovascular Outcomes.

ConsensusScore™: Results are generally consistent across studies.

Ranked evidence signals

1
All-cause mortality
EvidenceScore™ Limited | EvidenceScore™ 34.2 | neutral | ConsensusScore™ Unclear | 1 study

Why this answer: This answer is based on 9 supporting studies with generally consistent results and a positive effect signal.

Limitations

Population details are unavailable.

View Full Evidence

Does GLP-1 Receptor Agonists affect hypoglycemia?

Limited Evidence

Current evidence does not show a clear benefit of GLP-1 Receptor Agonists for Hypoglycemia.

ConsensusScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

1
Hypoglycemia events
EvidenceScore™ Limited | EvidenceScore™ 34.2 | neutral | ConsensusScore™ Unclear | 1 study

Why this answer: This answer is based on 11 supporting studies and existing graph evidence signals.

Limitations

Consistency cannot yet be determined.
Population details are unavailable.

View Full Evidence

Does GLP-1 Receptor Agonists affect gastrointestinal adverse events?

Limited Evidence

Current evidence does not show a clear benefit of GLP-1 Receptor Agonists for Gastrointestinal Adverse Events.

ConsensusScore™: Results are mixed and should be interpreted cautiously.

Evidence caveat: The available evidence reports mixed findings.

Ranked evidence signals

1
Gastrointestinal disorders incidence
EvidenceScore™ Limited | EvidenceScore™ 25.4 | moderate negative | ConsensusScore™ Unclear | 1 study

Why this answer: This answer is cautious because the available studies report mixed findings.

Limitations

Population details are unavailable.

View Full Evidence

Does Liraglutide improve incidence of vascular events within 90 days?

Emerging Evidence

Liraglutide appears to improve Incidence of vascular events within 90 days.

ConsensusScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

1
Incidence of vascular events within 90 days
EvidenceScore™ Emerging | EvidenceScore™ 51.7 | strong positive | ConsensusScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

Only one supporting study is available.
Consistency cannot yet be determined.
Population details are unavailable.

View Full Evidence

Learn how Evidence Intelligence™ works

Next steps

Continue your research

Choose a next path through related evidence topics, archive views, and research summaries.

Evidence topics

Follow the topics this study contributes to.

Cardiovascular Risk Evidence Hub GLP-1 Receptor Agonists Evidence Hub Liraglutide Evidence Hub

Explore in archive

Open broader archive views for this relationship.

All studies on Liraglutide and Ischemic stroke All studies on Liraglutide and Stroke recurrence All studies on Liraglutide and Hemorrhagic stroke All studies on Liraglutide and Incidence of vascular events within 90 days

Related research

Read related research summaries.

Liraglutide is well tolerated in diabetes patients undergoing hemodialysis.Liraglutide improves glycaemic control in adults with T2D HbA1c mediates cardiovascular benefits of GLP-1 receptor agonists Metformin and glimepiride with basal insulin lowered HbA1c the most Triple combination therapy lowered HbA1c more than dual therapy in type 2 diabetes

No ads. No tracking.

Focused on evidence, not advertising.

Secure & private

Your data is always protected.

Always up to date

New studies added every day.